Credit: Pitju/Getty Images
Researchers have developed a new classification of cognitive function for patients with multiple sclerosis (MS) that is based on the identification of five cognitive phenotypes.
Researchers have found that administering a drug for multiple sclerosis (MS) significantly improves cognitive processing speed in patients who have secondary progressive MS compared with placebo, according to a new study.
Exercising the mind through cognitive rehabilitation is now a recommended intervention for the many individuals with multiple sclerosis (MS) who experience difficulties with memory, thinking, and other brain functions. Could exercising the body be too far behind?
For individuals with multiple sclerosis the experience of aging appears to follow along one of two paths – some people feel their preexisting disability gives them an advantage in coping and tolerating age-related difficulties, while others feel more acutely the double burdens of MS and aging.
Mindfulness-based interventions such as day wellness programs have the potential to improve mood and overall emotional awareness in people with multiple sclerosis (MS), according to preliminary results of two small, early-phase studies presented at the 2020 virtual meeting of the Consortium of Multiple Sclerosis Centers.
The first symptoms to come to mind at the mention of multiple sclerosis (MS) are likely to be walking difficulty, vision problems, and increased fatigue. During the past 25 years, many therapies that effectively reduce these symptoms have been introduced. These therapeutic successes have enabled researchers and neurologists to focus on an aspect of MS that sometimes has been overlooked: cognitive symptoms.
During the past few decades, research has made clear that multiple sclerosis causes not only physical disability but also cognitive problems.
Multiple sclerosis patients who are young, male and have mild disability are more likely to be employed, based on a recent analysis of multiple sclerosis registries across North America, Germany, and the United Kingdom.
The way Frederick W. Foley, PhD, sees it, screening for cognitive problems in patients with multiple sclerosis has been taking a back seat to other routine clinical assessments largely because the deficits aren’t obvious in a typical clinical examination.
“I can’t do that, I have MS.” Those are the seven words Megan Weigel, DNP, ARNP-c, MSCN, typically hears when she initially suggests yoga classes to her patients with multiple sclerosis. Her response to their protests is simple: “Yes, you can.”